Jazz Pharma Plc (JAZZ) 120.84 $JAZZ
Jazz Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.43%
Comtex SmarTrend(R) - Thu Sep 01, 1:38PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $121.55 to a high of $124.25. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $123.52 on volume of 328,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 120.84 (-2.47)
Weakness Seen in Jazz Pharmaceuticals (JAZZ) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:32AM CDT
Jazz Pharmaceuticals (JAZZ) has witnessed a significant price decline and negative trend in earnings estimate revisions in the past four weeks
BSTC: 36.56 (-0.99), JAZZ: 120.84 (-2.47)
Jazz Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 5.10%
Comtex SmarTrend(R) - Wed Aug 10, 12:57PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $140.51 to a high of $147.75. Yesterday, the shares fell 5.1%, which took the trading range below the 3-day low of $148.42 on volume of 833,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 120.84 (-2.47)
Jazz (JAZZ) Q2 Earnings Up Y/Y, Lowers Earnings Outlook
Arpita Dutt - Zacks Investment Research - Wed Aug 10, 6:55AM CDT
Jazz (JAZZ) updated its 2016 guidance to reflect the Celator acquisition and the modification in the calculation of non-GAAP income tax provision.
JAZZ: 120.84 (-2.47), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Jazz Pharmaceuticals Announces Second Quarter 2016 Financial Results
PR Newswire Europe - Tue Aug 09, 3:06PM CDT
Strong Top- and Bottom-line Growth
JAZZ: 120.84 (-2.47)
Jazz (JAZZ) Q2 Earnings: Will the Stock Disappoint?
Arpita Dutt - Zacks Investment Research - Fri Aug 05, 6:45AM CDT
Our proven model does not conclusively show that Jazz (JAZZ) is likely to beat earnings estimates this quarter.
IPXL: 24.03 (+0.09), ADHD: 4.77 (+0.03), JAZZ: 120.84 (-2.47), INCY: 82.02 (+1.21)
Hercules Announces Strong Second Quarter Financial Results with $0.32 NII per Share and a $0.31 Quarterly Dividend
BusinessWire - Thu Aug 04, 3:05PM CDT
--Q2 2016 Financial Highlights
TPIC: 19.52 (-0.27), HTGC: 13.76 (+0.07), NUAN: 14.90 (+0.30), PFE: 34.77 (+0.09), BIND: 0.78 (-0.09), RLOC: 4.60 (unch), CPXX: 30.24 (unch), HTGY: 25.86 (+0.02), HTGZ: 25.60 (+0.01), GCI: 11.99 (+0.22), HTGX: 26.15 (+0.01), JAZZ: 120.84 (-2.47), ANAC: 99.06 (-0.14), EACQ: 9.95 (+0.22)
CMS Grants New Technology Add-On Payment to Defitelio for the Treatment of Hepatic Veno-Occlusive Disease with Renal or Pulmonary Dysfunction Following Hematopoietic Stem-Cell Transplantation
PR Newswire Europe - Tue Aug 02, 6:18PM CDT
Add-On Payment to Provide Additional Medicare Reimbursement for Defitelio and to Support Patient Access in the Inpatient PPS Hospital Setting
JAZZ: 120.84 (-2.47)
Covered Call reports for Marathon Oil Corporation, Amazon.com, Jazz Pharmaceuticals, Kellogg Company and Nike include trade ideas that offer returns of 20% or more!
PR Newswire - Fri Jul 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMZN, JAZZ, K, MRO, and NKE.
AMZN: 772.44 (+1.82), NKE: 58.02 (-0.52), JAZZ: 120.84 (-2.47), MRO: 15.49 (+0.38), K: 82.42 (+0.73)
Jazz Pharmaceuticals and Pfenex Enter into a Worldwide License and Option Agreement Related to Product Candidates in Early Development for Hematological Malignancies
PR Newswire Europe - Thu Jul 28, 3:06PM CDT
Jazz Pharmaceuticals plc and Pfenex Inc. today announced an agreement under which Pfenex granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage hematology product candidates. The agreement also includes an option for Jazz Pharmaceuticals to negotiate a license for a recombinant pegaspargase product candidate with Pfenex. This early development stage collaboration demonstrates Jazz Pharmaceuticals' focus on identifying innovative technologies that may lead to the development of important therapeutic options for patients with hematological malignancies.
JAZZ: 120.84 (-2.47), PFNX: 7.29 (+0.14)
After Yesterday's Decline of 2.80%, Jazz Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jun 21, 2:18PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $139.52 to a high of $144.95. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $142.42 on volume of 400,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 120.84 (-2.47)
Watch for Jazz Pharmaceuticals to Potentially Rebound After Falling 1.10% Yesterday
Comtex SmarTrend(R) - Fri Jun 17, 2:51PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $142.42 to a high of $146.74. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $143.66 on volume of 267,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 120.84 (-2.47)
Jazz Pharmaceuticals Offers HAL Study Data on JZP-110
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:42AM CDT
Jazz (JAZZ) presented new data from a Human Abuse Liability (HAL) study on JZP-110 at the annual meeting of the Associated Professional Sleep Societies.
ANIP: 59.86 (-1.56), JAZZ: 120.84 (-2.47), PFE: 34.77 (+0.09), BMY: 56.35 (-0.41)
Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability (HAL) Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting
PR Newswire Europe - Tue Jun 14, 8:05AM CDT
Jazz Pharmaceuticals plc today announced results from a Human Abuse Liability (HAL) study of JZP-110, an investigational wake-promoting agent in Phase 3 development for the treatment of excessive sleepiness (ES) in adult patients with narcolepsy or with obstructive sleep apnea (OSA). The data will be presented today at the 30th Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting, taking place June 11-15, 2016 in Denver, Colorado.
JAZZ: 120.84 (-2.47)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Celator Pharmaceuticals, Inc. - CPXX
ACCESSWIRE - Wed Jun 08, 5:36PM CDT
BALA CYNWYD, PA / ACCESSWIRE / June 8, 2016 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc. ("Celator" or "the Company"
(Nasdaq: CPXX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Jazz Pharmaceuticals plc, ("Jazz".
CPXX: 30.24 (unch), JAZZ: 120.84 (-2.47)
Jazz Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.43%
Comtex SmarTrend(R) - Thu Sep 01, 1:38PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $121.55 to a high of $124.25. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $123.52 on volume of 328,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 120.84 (-2.47)
Weakness Seen in Jazz Pharmaceuticals (JAZZ) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:32AM CDT
Jazz Pharmaceuticals (JAZZ) has witnessed a significant price decline and negative trend in earnings estimate revisions in the past four weeks
BSTC: 36.56 (-0.99), JAZZ: 120.84 (-2.47)
Jazz Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 5.10%
Comtex SmarTrend(R) - Wed Aug 10, 12:57PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $140.51 to a high of $147.75. Yesterday, the shares fell 5.1%, which took the trading range below the 3-day low of $148.42 on volume of 833,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 120.84 (-2.47)
Jazz (JAZZ) Q2 Earnings Up Y/Y, Lowers Earnings Outlook
Arpita Dutt - Zacks Investment Research - Wed Aug 10, 6:55AM CDT
Jazz (JAZZ) updated its 2016 guidance to reflect the Celator acquisition and the modification in the calculation of non-GAAP income tax provision.
JAZZ: 120.84 (-2.47), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Jazz Pharmaceuticals Announces Second Quarter 2016 Financial Results
PR Newswire Europe - Tue Aug 09, 3:06PM CDT
Strong Top- and Bottom-line Growth
JAZZ: 120.84 (-2.47)
Jazz (JAZZ) Q2 Earnings: Will the Stock Disappoint?
Arpita Dutt - Zacks Investment Research - Fri Aug 05, 6:45AM CDT
Our proven model does not conclusively show that Jazz (JAZZ) is likely to beat earnings estimates this quarter.
IPXL: 24.03 (+0.09), ADHD: 4.77 (+0.03), JAZZ: 120.84 (-2.47), INCY: 82.02 (+1.21)
Hercules Announces Strong Second Quarter Financial Results with $0.32 NII per Share and a $0.31 Quarterly Dividend
BusinessWire - Thu Aug 04, 3:05PM CDT
--Q2 2016 Financial Highlights
TPIC: 19.52 (-0.27), HTGC: 13.76 (+0.07), NUAN: 14.90 (+0.30), PFE: 34.77 (+0.09), BIND: 0.78 (-0.09), RLOC: 4.60 (unch), CPXX: 30.24 (unch), HTGY: 25.86 (+0.02), HTGZ: 25.60 (+0.01), GCI: 11.99 (+0.22), HTGX: 26.15 (+0.01), JAZZ: 120.84 (-2.47), ANAC: 99.06 (-0.14), EACQ: 9.95 (+0.22)
CMS Grants New Technology Add-On Payment to Defitelio for the Treatment of Hepatic Veno-Occlusive Disease with Renal or Pulmonary Dysfunction Following Hematopoietic Stem-Cell Transplantation
PR Newswire Europe - Tue Aug 02, 6:18PM CDT
Add-On Payment to Provide Additional Medicare Reimbursement for Defitelio and to Support Patient Access in the Inpatient PPS Hospital Setting
JAZZ: 120.84 (-2.47)
Covered Call reports for Marathon Oil Corporation, Amazon.com, Jazz Pharmaceuticals, Kellogg Company and Nike include trade ideas that offer returns of 20% or more!
PR Newswire - Fri Jul 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMZN, JAZZ, K, MRO, and NKE.
AMZN: 772.44 (+1.82), NKE: 58.02 (-0.52), JAZZ: 120.84 (-2.47), MRO: 15.49 (+0.38), K: 82.42 (+0.73)
Jazz Pharmaceuticals and Pfenex Enter into a Worldwide License and Option Agreement Related to Product Candidates in Early Development for Hematological Malignancies
PR Newswire Europe - Thu Jul 28, 3:06PM CDT
Jazz Pharmaceuticals plc and Pfenex Inc. today announced an agreement under which Pfenex granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage hematology product candidates. The agreement also includes an option for Jazz Pharmaceuticals to negotiate a license for a recombinant pegaspargase product candidate with Pfenex. This early development stage collaboration demonstrates Jazz Pharmaceuticals' focus on identifying innovative technologies that may lead to the development of important therapeutic options for patients with hematological malignancies.
JAZZ: 120.84 (-2.47), PFNX: 7.29 (+0.14)
After Yesterday's Decline of 2.80%, Jazz Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jun 21, 2:18PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $139.52 to a high of $144.95. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $142.42 on volume of 400,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 120.84 (-2.47)
Watch for Jazz Pharmaceuticals to Potentially Rebound After Falling 1.10% Yesterday
Comtex SmarTrend(R) - Fri Jun 17, 2:51PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $142.42 to a high of $146.74. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $143.66 on volume of 267,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 120.84 (-2.47)
Jazz Pharmaceuticals Offers HAL Study Data on JZP-110
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:42AM CDT
Jazz (JAZZ) presented new data from a Human Abuse Liability (HAL) study on JZP-110 at the annual meeting of the Associated Professional Sleep Societies.
ANIP: 59.86 (-1.56), JAZZ: 120.84 (-2.47), PFE: 34.77 (+0.09), BMY: 56.35 (-0.41)
Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability (HAL) Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting
PR Newswire Europe - Tue Jun 14, 8:05AM CDT
Jazz Pharmaceuticals plc today announced results from a Human Abuse Liability (HAL) study of JZP-110, an investigational wake-promoting agent in Phase 3 development for the treatment of excessive sleepiness (ES) in adult patients with narcolepsy or with obstructive sleep apnea (OSA). The data will be presented today at the 30th Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting, taking place June 11-15, 2016 in Denver, Colorado.
JAZZ: 120.84 (-2.47)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Celator Pharmaceuticals, Inc. - CPXX
ACCESSWIRE - Wed Jun 08, 5:36PM CDT
BALA CYNWYD, PA / ACCESSWIRE / June 8, 2016 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc. ("Celator" or "the Company"
(Nasdaq: CPXX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Jazz Pharmaceuticals plc, ("Jazz". CPXX: 30.24 (unch), JAZZ: 120.84 (-2.47)
